Source link : https://www.newshealth.biz/health-news/immunotherapy-may-not-benefit-all-gastroesophageal-cancer-patients-fda-staff-says/
An FDA advisory committee will consider whether PD-L1 expression cutoffs should guide use of checkpoint inhibitors to treat advanced gastroesophageal cancers. Current approved indications for three different PD-1/PD-L1 inhibitors allow use of the drugs in advanced gastroesophageal cancers irrespective of PD-L1 expression levels. FDA staff reports suggest the agency might want to rethink those approvals […]
Author : News Health
Publish date : 2024-09-24 20:25:24
Copyright for syndicated content belongs to the linked Source.
Categories